Latest Hotspot

Arvinas and Novartis Seal Global Licensing Deal for Prostate Cancer Therapy ARV-766

16 April 2024
3 min read

Arvinas, Inc., an enterprise operating at the clinical phase in the biotechnological sector, focused on pioneering a novel category of pharmaceuticals through the targeted protein degradation approach, has revealed its entry into a sole comprehensive licensing contract with the global healthcare giant Novartis. The agreement encompasses the international advancement and marketing rights for their investigational compound, ARV-766.

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.

图形用户界面, 应用程序, 电子邮件

描述已自动生成

Arvinas is advancing its progressive PROTAC technology by transferring its second-generation androgen receptor (AR) degrader designed to combat prostate cancer. This shift includes a deal where Arvinas will sell its AR-V7 program that's still in the early stages of development to Novartis.

"It's incredibly exciting to align with an entity that echoes our commitment to pioneering critical treatments for patients with grave health conditions," stated John Houston, Ph.D., the leader, president, and CEO at Arvinas. "Novartis' knowledge and resources are expected to enhance the progression of ARV-766, increasing its prospects of becoming a premier and unrivaled therapy for individuals facing prostate cancer. Our agreement further acknowledges the groundbreaking nature of our PROTAC technology in creating novel therapies."

As per the agreement's provisions, Novartis gains complete responsibility for global clinical trials, market introduction, and overall rights tied to research, development, production, and market launch related to the AR-V7 project in its early stages. Arvinas will initially obtain a payment totaling $150 million. Furthermore, according to the Licensing Agreement, Arvinas stands to gain additional payments linked to development milestones and regulatory and sales benchmarks, potentially accumulating in excess of $1.01 billion, along with staggered royalties for ARV-766.

The deal's finalization is contingent upon both parties obtaining requisite clearances or endorsements, which includes the lapse or conclusion of the review period as stipulated by the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Goldman Sachs & Co. LLC serves as Arvinas' sole financial consultant for this transaction.

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 表格

描述已自动生成

According to the data provided by the Synapse Database, As of April 15, 2024, there are 261 investigational drugs for the AR target, including 210 indications, 321 R&D institutions involved, with related clinical trials reaching 2150, and as many as 180372 patents.

ARV-766 is a PROTACs drug that targets the androgen receptor and is primarily used for the treatment of prostatic cancer and metastatic prostatic cancer. It falls under the therapeutic areas of neoplasms and urogenital diseases. Luxdegalutamide has reached Phase 2 of clinical development, indicating promising progress in its evaluation as a potential treatment option.

图形用户界面, 文本, 应用程序

描述已自动生成

How to search for global clinical trial information on drugs?
Knowledge Base
3 min read
How to search for global clinical trial information on drugs?
16 April 2024
Information on ongoing clinical drug trials worldwide can be accessed through the several channels.
Read →
Alpine Immune Sciences Unveils Latest Trial Results for Povetacicept Treating IgA Kidney Disease
Latest Hotspot
4 min read
Alpine Immune Sciences Unveils Latest Trial Results for Povetacicept Treating IgA Kidney Disease
16 April 2024
Alpine Immune Sciences Reports New Clinical Data for Povetacicept in IgA Nephropathy.
Read →
How to Obtain Global New Drug Research and Development Trends?
Knowledge Base
2 min read
How to Obtain Global New Drug Research and Development Trends?
16 April 2024
Several approaches can be employed to swiftly follow the latest global developments in new drug research and development.
Read →
Macomics Unveils Breakthrough Anti-LILRB Antibody at 2024 AACR with Promising Preclinical Data
Latest Hotspot
3 min read
Macomics Unveils Breakthrough Anti-LILRB Antibody at 2024 AACR with Promising Preclinical Data
16 April 2024
Macomics Discloses Pioneering Anti-Pan-LILRB Antibody Initiative, Showcasing Encouraging Preclinical Results at 2024 AACR Event.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.